← Leaderboards
Bo Yu
Larix Bioscience, Llc
$3,630,091
Attributed
$7,342,417
Total exposure
21
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2015–22$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$6,790,885 · 20
CDC$551,532 · 1
By mechanism
R43$4,897,434 · 19
R44$2,444,983 · 2
Top collaborators
- James W Larrick22 shared
- Andrew R Mendelsohn2 shared
- Shawn Mojtahedian1 shared
- Mohammad Nasir Uddin1 shared
Others in their field
Top investigators on “Pre-Clinical”
- Leonard Freedman · Leidos Biomedical Research, Inc.$264,541,531
- Dennis R. Burton · Scripps Research Institute$257,157,696
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barton F Haynes · Duke University$186,001,832
- David Heimbrook · Leidos Biomedical Research, Inc.$151,740,590
- Reisa A. Sperling · Banner Health$137,047,788
Research focus
Pre-ClinicalAntibodiesDrug KineticsToxic EffectAffinityBaseIn VivoBindingAnimalsAnimal ModelIn VitroPreventMouse ModelMediatingMonoclonal AntibodiesHuman Monoclonal AntibodiesAffectAssay DevelopmentSignal TransductionSafetyProductionEffective TherapyCellsIn Vitro Activity
Grant awards (24)
Advancing a novel therapy for preeclampsia$385,000
R43 · FY2022 · HD · contact PI
PA21-259, PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical$275,766
R43 · FY2022 · GH · contact PI
Pan-COVID Therapeutic$275,766
R43 · FY2022 · GH · contact PI
Therapeutic antibody for anorexia nervosa$259,606
R43 · FY2022 · MH · contact PI
Therapeutic antibody for cancer-associated cachexia$252,282
R43 · FY2021 · CA · contact PI
Novel therapy for myocardial ischemia-reperfusion injury$252,000
R43 · FY2021 · HL · contact PI
Inhibiting GPR146 in hypercholesterolemia$249,734
R43 · FY2021 · HL · contact PI
Targeted therapeutic for Netherton syndrome$252,000
R43 · FY2020 · AR · contact PI
Targeted Therapy for Type 1 diabetes$250,000
R43 · FY2020 · DK · contact PI
Novel anti-fibrotic therapy for IPF$224,924
R43 · FY2020 · HL · contact PI
Dual Intracellular and Extracellular Expression Technology (dIEE) for Parkinsonâs Disease$225,000
R43 · FY2019 · NS · contact PI
Targeting TGF-beta activation in tumors$224,981
R43 · FY2019 · CA · contact PI
Human glyco-engineered CHO cells$788,585
R44 · FY2018 · GM · contact PI
Novel GPCR-targeted therapy for preeclampsia$224,986
R43 · FY2018 · HD · contact PI
Dual Intracellular and Extracellular Expression Technology (dIEE) for AlzheimerÃÂÃÂÃÂâÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂs Disease$224,981
R43 · FY2018 · AG · contact PI
Targeting innate immunity in Type 1 diabetes$224,981
R43 · FY2018 · DK · contact PI
Novel therapy for atopic dermatitis$224,981
R43 · FY2018 · AI · contact PI
Human glyco-engineered CHO cells$700,809
R44 · FY2017 · GM · contact PI
Novel monobody therapy for pancreatic cancer$224,981
R43 · FY2017 · CA · contact PI
Novel targeted therapeutic for advanced metastatic disease$224,981
R43 · FY2017 · CA · contact PI
Novel therapy for Goodpasture syndrome$224,393
R43 · FY2017 · DK · contact PI
Antibody-Membrane Switch (AMS) technology for optimized antibody engineering$455,800
R44 · FY2016 · AI
Antibody-Membrane Switch (AMS) technology for optimized antibody engineering$499,789
R44 · FY2015 · AI
Human Glyco-engineered CHO Cells$196,091
R43 · FY2015 · GM · contact PI